How effective and safe is Naftifine 2% compared to Luliconazole 1% for treating Ringworm skin infection at a tertiary care hospital
Not Applicable
- Conditions
- Health Condition 1: B354- Tinea corporis
- Registration Number
- CTRI/2024/04/065336
- Lead Sponsor
- DR R SUGANYA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients above the age of 18 years of either sex who were clinically and mycologically diagnosed of a case of localized dermatophytosis were included in the study.
Exclusion Criteria
Patients with extensive dermatophytosis, other forms of tinea infections
Superadded bacterial infection
Immunocompromised patients
Dermatitis such as contact dermatitis, atopic dermatitis, psoriasis, other skin diseases
Use of corticosteroids in the last 4 weeks.
Pregnant and lactating mothers
Patients with a history of hypersensitivity to azole antifungals
Patients who received topical antifungal within 1 week before baseline visit and patients who received systemic antifungals within 4 weeks before baseline were excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method